| Autor: |
Stec, Albert, Maciejewska, Magdalena, Paralusz-Stec, Karolina, Michalska, Milena, Giebułtowicz, Joanna, Rudnicka, Lidia, Sikora, Mariusz |
| Předmět: |
|
| Zdroj: |
Journal of Inflammation Research; May2023, Vol. 16, p1895-1904, 10p |
| Abstrakt: |
Objective: To determine concentrations of the bacteria-derived metabolite TMAO in patients with systemic sclerosis and to assess possible correlation between TMAO and a specific manifestation of the disease. Patients and Methods: The study included 63 patients with SSc and 47 matched control subjects. The concentration of TMAO was measured with high-performance liquid chromatography. Results: Plasma TMAO level was significantly increased in patients with SSc (283.0 [188.5– 367.5] ng/mL versus 205.5 [101.0– 318.0] ng/mL; p < 0.01). An increased concentration of TMAO was observed in patients with concomitant interstitial lung disease (ILD) (302.0 ng/mL [212.0– 385.5] ng/mL versus 204.0 [135.5– 292.0] ng/mL; p < 0.01) and esophageal dysmotility (289.75 [213.75– 387.5] ng/mL versus 209.5 ng/mL [141.5– 315.0] ng/mL; p < 0.05) compared to patients without these complications. Furthermore, TMAO concentration exhibited significant correlation with markers of heart involvement (left ventricle ejection fraction, NT-proBNP), marker of ILD severity and Scleroderma Clinical Trials Consortium Damage Index. Conclusion: The concentration of TMAO, gut microbiota-associated metabolite, is increased in systemic sclerosis, particularly in patients with advanced organ involvement. This is the first study evaluating plasma TMAO in systemic sclerosis. Bacterial metabolites may be a link between dysbiosis and organ involvement in the course of the disease. Modulation of gut bacterial-derived metabolites may represent a new therapeutic approach in the management of systemic sclerosis. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
